|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash | |||||||||
| Prepaid expenses | |||||||||
| Short-term prepaid insurance | |||||||||
| Cash and cash equivalents | |||||||||
| Short-term investments | |||||||||
| Accounts receivable, net | |||||||||
| Prepaid expenses and other current assets | |||||||||
| Capitalized transaction costs (Note 2) | |||||||||
| Total current assets | |||||||||
| Deferred offering costs | |||||||||
| Long-term prepaid insurance | |||||||||
| Investments held in Trust Account | |||||||||
| Property and equipment, net | |||||||||
| Operating lease right-of-use assets, net | |||||||||
| Restricted cash | |||||||||
| Deposits | |||||||||
| Total assets | |||||||||
| LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' DEFICIT | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | |||||||||
| Accrued expenses | |||||||||
| Promissory note - related party | |||||||||
| Accrued offering costs | |||||||||
| Cash underwriting fee payable | |||||||||
| Long-term debt, current portion, net ($19,175 at fair value and $96 at amortized cost, net as of December 31, 2025) (Note 8) | |||||||||
| Deferred revenue | |||||||||
| Contract loss provision | |||||||||
| Operating lease liabilities, current | |||||||||
| Long-term debt, current portion, net | |||||||||
| Convertible promissory notes (Note 8) | |||||||||
| Total current liabilities | |||||||||
| Deferred underwriting fee | |||||||||
| Deferred underwriting fee payable | |||||||||
| Deferred underwriting fee payable | |||||||||
| Operating lease liabilities, non-current | |||||||||
| Warrant liabilities (Note 9) | |||||||||
| Long-term debt, non-current portion, net ($12,207 at fair value and $577 at amortized cost, net as of December 31, 2025) (Note 8) | |||||||||
| Total liabilities | |||||||||
| Series A Preferred Stock and Redeemable convertible preferred stock | |||||||||
| Class A Ordinary Shares | |||||||||
| Series A Preferred Stock | |||||||||
| Redeemable convertible preferred stock | |||||||||
| Total series A Preferred Stock and Redeemable convertible preferred stock | |||||||||
| Stockholders' deficit: | |||||||||
| Common stock: $0.0001 par value; 800,000,000 and 138,655,675 shares authorized; 101,693,656 and 69,663,395 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||
| Class A Ordinary Shares | |||||||||
| Class B Ordinary Shares | |||||||||
| Total common stock: $0.0001 par value; 800,000,000 and 138,655,675 shares authorized; 101,693,656 and 69,663,395 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||
| Additional paid-in capital | |||||||||
| Accumulated deficit | |||||||||
| Total stockholders' deficit | |||||||||
| Total liabilities, mezzanine equity, and stockholders' deficit |
Loading...